FIB-4 Score of 0.71: Low Risk for Advanced Liver Fibrosis
A FIB-4 score of 0.71 indicates low risk for advanced liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH), requiring only routine reassessment every 1-3 years without further hepatology workup. 1
Risk Stratification
Your FIB-4 score of 0.71 falls well below the threshold of 1.3 (or 2.0 if you're over 65 years old) that defines low risk for advanced fibrosis. According to the 2024 EASL-EASD-EASO guidelines, individuals with FIB-4 below 1.3 can be assumed to be at low risk of MASH and advanced fibrosis 1. This threshold has a negative predictive value of ≥90% for excluding advanced fibrosis 2.
The 2021 Gastroenterology clinical care pathway reinforces this, stating that patients with FIB-4 scores below this cutoff "do not need further evaluation" 2.
Clinical Implications
- No immediate hepatology referral needed: Your score does not warrant specialist evaluation or additional testing such as liver elastography (FibroScan) or liver biopsy
- No advanced imaging required: Procedures like vibration-controlled transient elastography (VCTE) or magnetic resonance elastography (MRE) are not indicated at this risk level 1
- Standard metabolic risk factor management: Focus remains on addressing underlying conditions like diabetes, obesity, or metabolic syndrome through lifestyle modification
Important Caveat
Despite the high negative predictive value, FIB-4 will miss approximately 10% of individuals with advanced fibrosis 1. The test performs less optimally in certain populations, including elderly patients and those with type 2 diabetes 1. However, the guidelines acknowledge that "it has not been formally demonstrated that repeating FIB-4 over time is effective in picking up the remaining individuals" 1.
Follow-Up Recommendations
Repeat FIB-4 testing every 1-3 years is recommended for ongoing surveillance 1, 2. The 2021 clinical care pathway specifically suggests considering repeat testing in 2-3 years 2. This interval allows detection of disease progression while avoiding unnecessary healthcare burden.
If you have risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD)—such as type 2 diabetes, abdominal obesity with additional metabolic risk factors, or persistently elevated liver enzymes—maintain these surveillance intervals even with your current low score 1.
What to Monitor
Between FIB-4 assessments, watch for:
- Development of new metabolic risk factors (diabetes, significant weight gain)
- Persistently elevated liver enzymes (AST, ALT)
- Changes in platelet count
- Advancing age (which affects FIB-4 calculation and cutoff thresholds)
If any of these factors change substantially, earlier repeat testing may be warranted rather than waiting the full 1-3 year interval.